TransMedics(US:TMDX) Prnewswireยท2025-03-21 14:55Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against TransMedics Group, Inc. due to allegations of securities law violations, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by April 15, 2025 [2][4]. Group 1: Allegations Against TransMedics - The complaint alleges that TransMedics and its executives made false and misleading statements, failed to disclose the use of kickbacks, fraudulent overbilling, and coercive tactics to generate revenue [4]. - It is claimed that TransMedics engaged in unsafe practices, hid safety issues, and lacked proper safety oversight, which increased regulatory scrutiny and risk [4]. - The lawsuit asserts that the misleading statements about TransMedics' business and operations led to investor damages when the true details became public [4]. Group 2: Market Reaction - Following a report from Scorpion Capital on January 10, 2025, which described TransMedics as a significant healthcare fraud, the company's stock fell by 5.15% on that day and further declined by 6.9% on January 13, 2025 [5]. Group 3: Legal Proceedings - The lead plaintiff in the class action will be the investor with the largest financial interest who is also typical of the class members, overseeing the litigation on behalf of the class [6]. - Any member of the class can apply to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [6]. Group 4: Call for Information - Faruqi & Faruqi encourages individuals with information regarding TransMedics' conduct, including whistleblowers and former employees, to contact the firm [7].